Text Size

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

This study has been completed.
Sponsor:
Information provided by:
Manhattan Eye, Ear & Throat Hospital
ClinicalTrials.gov Identifier:
NCT00211445
First received: September 13, 2005
Last updated: September 27, 2007
Last verified: September 2007
History of Changes
  Purpose

Central serous choroidal (CSC) retinopathy is a disease of the macula characterized by exudation of fluid under the retina localized to the posterior pole as well as loss of vision. The etiology is unknown, but according to the studies this condition is more common in young males and is associated with type A personality. Clinically, CSC is characterized by serous retinal detachment and area of leakage of in the subretinal space. The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, there is an indication for focal laser photocoagulation therapy of the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of RPE thus rendering laser treatment ineffective.The purpose of this medical research study is to evaluate Verteporfin therapy as an approach which may benefit patients with CSC, based on observations in exudative type of AMD patients treated with Photodynamic Therapy using Verteporfin.


Condition Intervention Phase
Chronic Central Serous Chorioretinopathy
 Procedure: Photodynamic Therapy with Verteporfin
Drug: verteporfin
Drug: Verteporfin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Verteporfin
U.S. FDA Resources

Further study details as provided by Manhattan Eye, Ear & Throat Hospital:

Primary Outcome Measures:
  • mean change in VA (ETDRS) from baseline to 24 months [ Time Frame: 24 months ]
  • investigate the potential of photodynamic therapy using verteporpin in chronic central serous chorioretinopathy [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • mean change of VA(ETDRS), OCT, FA from baseline to 24 months [ Time Frame: 2 years ]

Enrollment: 11
Study Start Date: July 2002
Study Completion Date: January 2006
  Hide Detailed Description

Detailed Description:

7.1 Visit 1 - Screening Visit

The first visit by the patient is for the purpose of screening the patient for the study. This visit must occur within 1 week prior to the treatment visit. At this visit the investigator and the supporting staff will:

  1. Determine if the patient is eligible for enrollment in the study, explain the study to the patient, and obtain an informed consent from the patient. The form should be witnessed and documented by obtaining the patient's signature at this visit.
  2. Only one eye of the patient can be enrolled in the study. For patients with lesions in both eyes, the investigator may enroll the eye they deem most eligible or amenable to treatment.
  3. Record patient demographics, complete medical history and contact information on the initial visit form.

  4. Perform a complete eye examination including:

    i. visual acuity. ii. slit-lamp biomicroscopy. iii. dilated fundus examination.

  5. Obtain stereo color fundus photographs (30 degree field of view) of the study eye.
  6. Obtain sodium fluorescein angiogram of the study eye via digital imaging system.
  7. Obtain ICGA of the study eye. NOTE: If a patient presents with any acute illness during screening and the day of treatment administration, his entry into the study is deferred until the acute illness resolves.

7.2 Visit 2 - Treatment Visit (Day Zero)

At this visit the patient is assigned a Verteporfin-PDT laser energy delivery profile according to the scheme detailed in Section 5.1, above. The investigator and the supporting staff will:

  1. Perform an eye examination including best-corrected visual acuity using the EDTRS visual chart.
  2. The angiograms may need to be repeated if the previous angiograms were done more than 72 hours ago.
  3. Perform Verteporfin-PDT treatment. NOTE: If a patient presents with any acute illness during screening and the day of treatment administration, his entry into the study is deferred till the acute illness resolves.

7.3 Visit 3 & 4- First Post-treatment Follow-up Visit

The investigator will have the patient return to the office after 2 weeks (Visit 3) and 6 weeks (Visit 4) after performing the Verteporfin-PDT treatment. At this visit the investigator and the supporting staff will:

  1. Perform a complete eye examination including

    1. best corrected visual acuity using EDTRS visual acuity chart.
    2. slit-lamp biomicroscopy.
    3. dilated fundus examination.
  2. Obtain stereo color fundus photographs (30 degree field of view) of the study eye.
  3. Obtain sodium fluorescein angiogram of the study eye via digital imaging system.
  4. Obtain ICGA of the study eye.
  5. Ask the patient about any new ocular or systemic symptoms that developed since last visit, and look for any associated signs and record both on the case report forms.
  6. Ask the patient and record any new medications being used since the last visit.
  7. If the patient is re-treated then the post-treatment visit schedule will start again at visit 3 as detailed in Section 7.3 Visit 3.

7.4 Visit 5 through Visit 12 - Follow-up Visits

The investigator will have the patient return to the office at 3-month (plus/minus 2 weeks) intervals after performing the last Verteporfin-PDT treatment. The visit windows are continuous, but two consecutive visits should not be scheduled within 2 weeks of each other. At these visits the investigator and the supporting staff will:

  1. Perform a complete eye examination including

    1. best corrected visual acuity using EDTRS visual acuity chart.
    2. slit lamp biomicroscopy.
    3. dilated fundus examination.
  2. Obtain stereo color fundus photographs (30 degree field of view) of the study eye.
  3. Obtain sodium fluorescein angiogram of the study eye.
  4. Obtain ICGA of the study eye.
  5. Ask the patient about any ocular or systemic symptoms, and look for any associated signs and record both on the case report forms.
  6. Ask the patient and record any medications being used.
  7. Based on the eye examination and the ICGA the investigator must decide whether any new or previously treated CNV vessels need to be treated.
  8. Perform any additional or concomitant treatment as required.
  9. At the final visit (approximately 24 months after entry into the study), the patient will be terminated from the study.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration.Chronic central serous chorioretinopathy could be defined on the basis of two factors: a) persistence of the detachment for more than 6 months and b) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.
  2. VA 20/40 and 20/320 Study Eye on the ETDRS visual acuity chart.
  3. VA 20/800 or better Fellow Eye on the ETDRS visual acuity chart.

Exclusion Criteria:

  1. Patient with tears in retinal pigment epithelium.
  2. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
  3. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye.
  4. Patient participating in any other investigational drug study.
  5. Inability to obtain photographs to document CNV (including difficulty with venous access).
  6. Patient with significant liver disease or uremia.
  7. Patient with known adverse reaction to indocyanine green or iodine.
  8. Patient is pregnant or nursing
  9. Age less than 18 years old
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00211445

Locations
United States, New York
Manhattan Eye, Ear & Throat Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Manhattan Eye, Ear & Throat Hospital
Investigators
Principal Investigator: Jason S. Slakter, MD Manhattan Eye, Ear & Throat Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00211445     History of Changes
Other Study ID Numbers: PDT for CSC
Study First Received: September 13, 2005
Last Updated: September 27, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Verteporfin
Photosensitizing Agents
 Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013